A resilient young boy from Russia battles neuroblastoma

There is a tough little fighter named Kuvatov Emin. He’s 8 years old, and he comes from Russia. Why do we admire his resilience? Here is his powerful story.

Emin was diagnosed with neuroblastoma over five years ago, staged as IV with bone marrow metastasis and MYCN gain. He underwent intensive induction chemotherapy, surgery, autologous stem cell transplant, and differentiation therapy, achieving initial remission. However, relapses occurred, involving bone and lymph nodes, despite second-line regimens like bevacizumab, irinotecan, temozolomide, and even allogeneic transplant. By 2025, MIBG scans revealed progression with new lesions, prompting his family to explore global options.

At BIOOCUS, Emin's case was evaluated for free by our specialists, who identified GD2 CAR-T as a promising salvage therapy. Following preconditioning with fludarabine and cyclophosphamide, the CAR-T cells were infused without complications. Expansion was robust, with absolute values rising significantly by day 7. Our team's vigilant monitoring prevented adverse events, and pathology confirmed the therapy's impact on his poorly differentiated tumor.

The advantages of BIOOCUS lie in our high-quality, patient-centered approach and groundbreaking CAR-T products. We deliver precision medicine in a supportive environment, with services including seamless international coordination, family counseling, and post-treatment tracking. Emin's parents commend the compassionate care that eased their worries during this critical time.